ServiceUpdated on 11 September 2025

BD Outreach (Japan): Pipeline Building & Deal Origination for CDMOs and Biotechs

About

LinkedIn isn’t where deals close here (only 2% of Japanese uses while 20-50% in EU) —targeted outreach and native-language follow-through are.

  • Ideal-customer profiling and account mapping across big pharma, specialty pharma, and innovators.

  • Multilingual outreach (JP/EN), discovery calls, and qualification to real opportunities.

  • RFQ/RFI orchestration for CDMOs; asset/optioning conversations for biotechs.

  • Investor lane: introductions to strategic pharma/CVC, family offices, and non-dilutive programs; deck/localization coaching.

  • Meeting sprints around BioJapan/CPHI Japan plus rolling roadshows; weekly cadence reports in JST.

  • Term-sheet choreography with “cultural translation” to keep momentum and protect value.
    Led by Moto Dohi (ex-Pfizer Japan; 10 years at a Swiss CDMO).

Type

  • Consulting

Applies to

  • Biotech and Lifescience